The DEA's Telehealth Prescribing Deadline in 2026: What December 31 Means for Your Online Care

During the COVID-19 public health emergency, the Drug Enforcement Administration (DEA) temporarily waived a long-standing requirement that patients see a prescriber in person before receiving a controlled substance. Those pandemic-era flexibilities have been extended four times, most recently through December 31, 2026.

Under the current flexibility, a DEA-registered practitioner can prescribe Schedule II–V controlled medications after a real-time video visit, with no prior in-person exam. That single waiver is what makes fully online treatment possible for millions of patients — including men receiving testosterone replacement therapy (TRT), which is a Schedule III controlled substance.

To be clear about what is not expiring: this deadline only applies to controlled substances. Most medications prescribed through telehealth are not controlled and are completely unaffected — more on that below.

The DEA's long-term plan is a "special registration" system — a framework it first proposed in January 2025 under the title Special Registrations for Telemedicine and Limited State Telemedicine Registrations. The proposal would create three new registration types allowing qualified telehealth practitioners and platforms to prescribe certain controlled medications remotely on a permanent basis, with added safeguards: prescription drug monitoring program checks, identity verification, clinician credentialing, and record-keeping requirements. The proposal drew more than 6,400 public comments, and it placed its tightest restrictions on Schedule II drugs (such as stimulants and strong opioids) rather than on Schedule III medications like testosterone.

On August 25, 2026, the DEA submitted the final version of that rule to the White House's Office of Information and Regulatory Affairs (OIRA) for review. As of early October it is still under review and the final text is not public. OIRA reviews typically take up to 90 days, which is why health-policy watchers expect movement before the end of the year.

That leaves three possible outcomes at year-end: the final rule is published and becomes the permanent framework; the DEA grants a fifth extension of the current flexibilities; or — the least likely scenario, and the one regulators have avoided four times already — the flexibilities lapse without a replacement.

This is the part most headlines skip, and it matters for anyone deciding whether to start treatment now.

Not affected at all (not controlled substances — telehealth prescribing continues as normal regardless of what happens in December):

• GLP-1 weight loss medications, including semaglutide and tirzepatide
• ED treatments such as sildenafil and tadalafil
• Hair loss treatments like finasteride and minoxidil
• Peptides such as sermorelin, and most wellness and preventive prescriptions

Affected (controlled substances that currently rely on the telehealth flexibility):

• Testosterone and other anabolic steroids (Schedule III) — the main one for men's health patients
• ADHD stimulant medications (Schedule II)
• Certain sleep and anxiety medications (Schedule IV)

If your treatment is in the first group, the December deadline is background noise. If you are on TRT — or thinking about starting it — the next two sections are for you.

First, nothing changes today. Through December 31, 2026, telehealth TRT works exactly as it has: an online evaluation, lab work, and a prescription from a licensed provider, with no in-person visit required by federal law (some states impose their own rules, which your provider must follow).

Second, the most likely outcome is continuity rather than cutoff. The proposed special registration framework was explicitly designed to keep legitimate telehealth prescribing alive, and testosterone sits in the less-restricted Schedule III tier of that proposal. Both an on-time final rule and another extension would preserve a telehealth pathway for TRT; what may change is paperwork on the provider's side — registrations, monitoring checks, and reporting that platforms will need to build into their workflow.

Third, prescriptions do not vanish at midnight. A valid prescription issued under the current rules remains valid. The deadline governs how new prescribing relationships are established, which is why starting treatment and getting your baseline labs done while the current rules are in force is the simplest way to protect your continuity of care.

This is also a good moment to remember that TRT is not a casual prescription under any framework. Responsible providers confirm low testosterone with morning blood tests before treating, screen for contraindications like prostate cancer and untreated sleep apnea, and monitor hematocrit and PSA during treatment. Common side effects can include acne, fluid retention, and effects on fertility — all reasons the decision belongs in a conversation with a licensed provider, telehealth or otherwise.

A few practical steps, whichever way the final rule lands. If you are an existing telehealth patient on a controlled medication, ask your provider how they are preparing for the year-end transition — reputable platforms have been tracking this rule for months. Keep your labs current, since up-to-date bloodwork makes any re-verification process faster. Refill on schedule rather than letting your supply run down in late December. And if you have been putting off an evaluation you already know you need, doing it under the current, well-understood rules is easier than doing it in the first weeks of a new system.

For everything that is not a controlled substance — weight loss, ED, hair loss, general wellness — there is no deadline and nothing to time. Telehealth access to those treatments is not part of this rulemaking.

JoeyMed connects you with licensed providers for weight loss treatment, sexual health, hair growth, and wellness and hormone health — including lab-based evaluations for men concerned about low testosterone. Every treatment decision is made with a licensed provider based on your health history and, where appropriate, bloodwork. If you have been waiting for the "right time" to get evaluated, the current rules make this a clear window: start your online visit today and have your plan in place well before the calendar turns.